Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.
BullFrog AI Holdings, Inc. uses artificial intelligence and machine learning to turn complex biomedical data into actionable insights for drug discovery and development. Company news centers on the bfLEAP® platform, data harmonization through bfPREP™, and bfARENAS™, a scenario-based decision engine for pharmaceutical portfolio strategy, target selection, biomarker strategy and clinical trial design.
Recurring updates also cover commercial feasibility agreements with pharmaceutical customers, research-institution collaborations, white papers and conference participation in life sciences and oncology. Corporate news includes Nasdaq continued-listing compliance, at-the-market and equity-line financing activity, balance-sheet updates, and shareholder communications tied to the company’s common stock and tradable warrants.
BullFrog AI Holdings (NASDAQ: BFRG; BFRGW), a leader in AI-driven drug discovery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company's CEO, Vin Singh, will deliver a presentation that will be available on demand starting September 9, 2024, at 7:00am ET. Interested parties can access live and archived webcasts of the event through BullFrog AI's investor relations website at investors.bullfrogai.com. This participation provides an opportunity for the company to showcase its advancements in AI-driven drug discovery to a global investment audience.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has announced significant progress in its collaboration with the Lieber Institute for Brain Development (LIBD) to uncover new insights into bipolar disorder (BD) pathways and potential drug targets. The research has identified specific molecular pathways associated with BD, enabling the discovery of new candidate drug targets.
Key findings include:
- Significant enrichment in 6 out of 68 clusters from the LIBD brain dataset
- Two substantially enriched clusters in the Dentate Gyrus
- One specific cluster associated with BD in the Dorsolateral Prefrontal Cortex
- Potential dysregulation of pro-inflammatory pathways
- Identification of novel pathways significant to BD pathophysiology
BullFrog AI is now focusing on validating these findings in wet lab settings and engaging with pharmaceutical partners to advance these discoveries.
BullFrog AI (NASDAQ: BFRG) is hosting a live investor webinar on June 12, 2024, at 4:15 p.m. ET, featuring insights from CSO Tom Chittenden and LIBD CEO Daniel Weinberger on their collaborative research. The study, using over 2,800 brain samples, has revealed novel insights into psychiatric conditions such as schizophrenia and bipolar disorder through advanced AI techniques. This collaboration has enabled clustering based on biological data, uncovering potential biomarkers and drug targets. The event aims to provide comprehensive details on these findings and discuss future revenue opportunities through potential pharmaceutical partnerships.
BullFrog AI and the Lieber Institute for Brain Development (LIBD) announced significant progress in their collaboration to identify novel drug targets for neuropsychiatric disorders. Using AI and machine learning, they have discovered patient subgroups within conditions like major depression, schizophrenia, and bipolar disorder. This approach led to identifying key genes that present new potential drug targets. BullFrog AI is applying Causal AI to validate these targets, aiming to develop targeted treatments for psychiatric disorders. The collaboration has also started engagements with pharmaceutical companies for strategic partnerships.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.